Nectar Lifesciences Ltd. · NSE:NECLIFE
Nectar Lifesciences — Q3 FY2025 Earnings Presentation
24 slides from Nectar Lifesciences's earnings presentation, Jan 31, 2025
Slide 1: Nectar Lifesciences Ltd. exchange filing cover letter
Nectar Lifesciences Ltd. Ref: NLL\CS\2025- 458 January 31, 2025 To 1. National Stock Exchange of India Limited 2. BSE Limited Listing Department, Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, P J Towers, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001 Symbol: NECLI
Slide 2: Nectar Lifesciences Limited Investor Presentation Q3 FY25
NECTAR LIFESCIENCES LIMITED A pioneer in cephalosporin manufacturing with global presence. Investor Presentation Q3 25
Slide 3: Disclaimer
DISCLAIMER In this presentation, we have disclosed forward- looking information.. This presentation is based on certain forward looking statements that we periodically make to anticipate results based on the management’s plans and assumptions. We have tried wherever possible to identify such stateme
Slide 4: Vision, Mission & Values
Vision, Mission & Values Mission - To alleviate human suffering with excellent global quality & affordable medicines created with a spirit of innovation, entrepreneurship & sustainability to create a better tomorrow. Vision - To become India's leading Global Life- Sciences company, which creates val
Slide 5: Content
Content 4 1 Financial Performance 2 About the Company 3 Business Performance & Financials 4 Industry Landscape 5 Growth Drivers 6 Outlook And Growth Strategy Confidential Copyright ©
Slide 6: Financial Performance
Financial Performance Revenue from Operations Period EBITDA Profit After Tax (Net of GST) ₹ 454.33 Crores ₹ 45.28 Crores ₹ 7.84 Crores Q3 FY 2025 (0.48% YoY growth) (6.12% YoY Growth) (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 C
Slide 7: About Our Business
ABOUT OUR BUSINESS Nectar Lifesciences Ltd Business Divisions Active Pharmaceutical Finished Dosage Empty Hard Gelatin Ingredients Capsules Forms Nectar PT Unipessoal LDA Portugal - Subsidiary Company for holding IPR
Slide 8: Leading Global Generic API and Formulation Company
Leading Global Generic API and Formulation Company Global Exports to over 45 countries Generic Cephalosporins and Non – Cephalosporins Diversified Business APIs and Formulations Expanding presence in regulated markets e.g. Regulated Markets Europe, Japan, Korea, China Manufacturing capabilities acro
Slide 9: Our Journey over the years
• Incorporated in Chandigarh • 400,000 sq. meter API • ~36,000 sq meter, API manufacturing Unit 2 was manufacturing Unit 1 inaugurated 2007 inaugurated 1995 • USFDA, EU GMP, PMDA, KFDA 2011 approvals attained for API facility 2008 • Collaboration with GSK kicked off ● Formulation Manufacturing Unit
Slide 10: Nectar's strong position in Cephalosporins
Nectar’s strong position in Cephalosporins Cephalosporins Integrated manufacturing Ecosystem ● Cephalosporins are high technology antibiotics used in the treatment of bacterial infections, especially for those ● Active Pharmaceutical Ingredients and Finished Dosage who are allergic to penicillin. Fo
Slide 11: Global Manufacturing Facilities
GLOBAL MANUFACTURING FACILITIES 29 years of Manufacturing Excellence Facilities Location Activity API Manufacturing Derabassi, Oral & Sterile Unit I Punjab Cephalosporin APIs API Manufacturing Derabassi, Oral & Sterile Unit II Punjab Cephalosporin APIs Formulation Cephalosporin FDFs Barotiwala, HP M
Slide 12: Nectar API and FDF Global Business Presence
Nectar API Global Business Presence Nectar FDF Global Business Presence
Slide 13: Diversified Revenue Base FY24
Diversified Revenue Base FY24 API Business Split FDF Business Split API API Exports Formulation Formulation Strong presence in Domestic Exports Domestic API and formulation 60% 40% 72% 28% business in nearly 45 countries.
Slide 14: Business Performance
Business Performance ○ Steady revenue growth despite industry-wide challenges. ○ Significant PAT growth in Q3 FY 25, reflecting operational efficiencies. ○ Improved EBITDA margins showcasing sustainable profitability.
Slide 15: Key Ratios
De <¢ NecLife 2000 1500 1000 500 o4 03 Sale Gross Margin Fv23 FY F249 M mnths FY 25 200 150 0.125 0.05 Key Ratios EBITDA ra ry ras FY24_ 9 Mouths FY EBITDA Margin Fy21 Fy22 Fy23 Fy24 9 Months FY 25 50 -50 0.02 -0.02 -0.04 -0.06 Net Profit FY24_ 9 Months FY 25
Slide 16: Performance Ratio
Performance Ratio ○ Demonstrating consistent operational efficiency. ○ Margins remain stable despite inflationary pressures.
Slide 17: Growth Vector
Growth Vector CDMO BUSINESS ● Strong focus on expanding the CDMO business of formulation , leveraging Integrated manufacturing capabilities. ● Positioned to strengthen customer relationships ● Focused on sustainable growth by reducing supply chain risks, lowering costs, improving ESG compliance, and
Slide 18: Export and Domestic Contribution
EXPORT AND DOMESTIC CONTRIBUTION
Slide 19: Industry Landscape: Global Cephalosporins Drug Market 2020-30
Industry Landscape: Global Cephalosporins Drug Market 2020-30 The global cephalosporin drugs market size was valued at USD 19.38 billion in 2023 and is growing at a rapid rate. Sources : Internal company information & https://www.grandviewresearch.com/industry-analysis/cephalosporin-drugs-market-rep
Slide 20: Growth Drivers
Growth Drivers State of the Art Established 29 years of Technologies and Relationships with Manufacturing Best in Class Sterile major Customers Excellence manufacturing & Suppliers facilities Strong commitment Robust R&D and to environment, dynamic team of health and safety professionals measures Co
Slide 21: Transformation Strategy
Transformation Strategy From API Dominance to Formulation Excellence Value in INR Crores ● Inhouse API-to-FDF integration and optimizing cost structures. 600 + ● Significant operational efficiencies, leading to 20% stronger financial performance through improved margins, better asset utilization, an
Slide 22: Reduction of Long Term Debt
Reduction of Long Term Debt ❖ Currently the company in Corporate Debt Restructuring(CDR) and WCTL Rs.61.90 Crs. ❖ On track to exit Corporate Debt Restructuring (CDR) by Jun.2026 and achieving lower interest rates and bank charges is expected to enhance profitability. ❖ Targeting Long term debt reduc
Slide 23: Outlook and Growth Strategy
Outlook and Growth Strategy Strategic Growth: Expanding market penetration in higher-margin API and formulations export markets to drive profitability. Debt Reduction: Actively pursuing debt reduction to lower interest costs and strengthen financial health. Capacity Expansion: Incremental capital ex
Slide 24: Thank You
THANK YOU www.neclife.com Investor relations email: cs@neclife.com
Nectar Lifesciences — Q3 FY2025 Earnings Presentation on 6ix